Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Stock up today ...

<< Previous

Bullboard Posts

Next >>

Comment by Marky1on Dec 28, 2020 8:23pm

191 Views

Post# 32189089

RE:RE:Stock up today ...

Sorry Doc....I'm definitely not in the same category as Mugsy! He is brilliant, and that's an understatement
We own a drug, that in my view and in the view of the people on BioPub, that will render and label an entire category of drugs as harmful and dangerous....I cannot see any reason why Anyone would not take otenaproxesul for their osteoarthritis and general pain problems

The largest category of medications are the NSAIDS family of drugs....Otenaproxesul is priceless in the hands of a lucky Pharma that buys the molecule

Thus I'd say that 346 is worth way over 2$B USD.....closer to 5$B
At least 50$ a share
iMHO

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario